Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OS002
- Development stage
- Preclinical
- Lead developer
- OmniSpirant
- Modality
- Stem Cell Therapies → Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Inhalation
01
Overview
OS002 is a preclinical-stage therapeutic candidate being developed by OmniSpirant for the treatment of Chronic Obstructive Pulmonary Disease (COPD). It is based on the company's proprietary OmniSome platform, which utilizes bioengineered extracellular vesicles (exosomes) derived from stem cells. These exosomes are designed to deliver therapeutic payloads directly to the lungs, likely via inhalation, to address the underlying pathology of chronic respiratory diseases. While the specific molecular target or payload for OS002 has not been publicly disclosed, the platform aims to leverage the regenerative and anti-inflammatory properties of stem cell-derived exosomes to provide a transformative treatment for COPD.
Beyond the preview
Go deeper on OS002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OS002.